Banking of corneal stromal lenticules: a risk-analysis assessment with the EuroGTP II interactive tool

Trias, Esteve; Gallon, Paola; Ferrari, Stefano; Piteira, Ana Rita; Tabera, Jaime; Casaroli-Marano, Ricardo P.; Parekh, Mohit; Ruzza, Alessandro; Franch, Antonella; Ponzin, Diego

doi:10.1007/s10561-020-09813-8

Cited by 7 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When using cryopreservation, lenticules are generally stored in liquid nitrogen at temperatures between −80 and −196 °C, and they can be stored in solutions that contain a cryopreservant such as dimethylsulfoxide (DMSO) or in tissue or dehydration mediums such as Dulbecco’s modified Eagle’s medium (DMEM), serum-free medium (SFM), silica gel, or glycerol [ 8 , 9 , 11 ]. Cryopreserving previously dehydrated lenticules is the most effective and economical form of long-term storage, and studies indicate that cryopreserved lenticules maintain their collagen structure and cellular viability with no significant difference in wound healing compared with fresh lenticules [ 6 – 8 , 11 ].…”

Section: Resultsmentioning

confidence: 99%

“…In conjunction, dehydrated lenticules maintain their biological and biomechanical properties, maintain corneal transparency, and show no difference in stiffness when compared with lenticules not dehydrated [ 8 , 9 ]. Agents that facilitate dehydration include silica gel, glycerol, or polyethylene glycol [ 12 – 14 ].…”

Section: Resultsmentioning

confidence: 99%

“…However, the antimicrobial properties of dehydrating agents such as glycerol provide more potent long-term preservation, and therefore, the benefits of dehydrating lenticules prior to cryopreserving them often outweigh the potential loss in lenticular thickness [ 7 ]. Studies indicate that cryopreservation maintains the collagen structure and cellular viability of the lenticule and that there is no significant difference in wound healing between fresh and cryopreserved lenticules [ 6 , 8 , 11 ]. Another study revealed that keratocytes and nerve fibers slowly integrated into the lenticular architecture, successfully combining cryopreserved lenticules within the host stroma [ 6 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Allogenic Lenticular Implantation for Correction of Refractive Error and Ectasia: Narrative Review

Moshirfar,

Stoakes,

Bruce

et al. 2023

Ophthalmol Ther

View full text Add to dashboard Cite

Introduction Intrastromal lenticule implantation is a promising treatment option for corneal pathologies, from refractive error to ectasia. In this narrative review, we intend to feature up-to-date literature supporting the use of lenticular tissue, a compelling method that can be customized for a variety of applications, providing an additional source of donor tissue for treating corneal diseases. Methods We searched databases PubMed, Mendeley, and Scopus last accessed 10 May 2023, for literature on stromal lenticules and narrowed based on relevance. Review articles, animal studies, ex vivo studies, and book chapters were excluded, while assessable and relevant articles published in English were included. Results Storage methods from using fresh lenticules to dehydration have proven successful, with cryopreservation maintaining structure and cellular viability for up to 10 years. Successful use of lenticules for treatment of numerous pathologies including corneal ectasias, hyperopia, and presbyopia with additional insight into the treatment of corneal ulcers and perforations are highlighted in this narrative review. Conclusion Lenticular implantation is an innovative and advantageous treatment for various ocular pathologies, offering increased bioavailability, flexibility, and customization for patients. They can treat previously untreatable diseases and serve as a replacement for synthetic implants, with promising outcomes worldwide. Lenticular implantation has the potential to become a leading approach in ophthalmologic surgery. Further studies should aim to provide evidentiary support for a standardization of lenticule banking.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Allogenic Lenticular Implantation for Correction of Refractive Error and Ectasia: Narrative Review

Moshirfar,

Stoakes,

Bruce

et al. 2023

Ophthalmol Ther

View full text Add to dashboard Cite

show abstract

“…Corneal stromal lenticules are the discarded tissue obtained following SMILE surgery and, in the recent years, their use in stromal engineering ( Wu et al, 2015 ; Damgaard et al, 2018 ; Mastropasqua et al, 2018 ; Nubile et al, 2021 ) has garnered considerable interest also related to important aspects, including minor ethical issues and the possibility to cryo-store them ( Ganesh et al, 2014 ; Liu et al, 2017 ) preserving their optical and biomechanical characteristics ( Li et al, 2012 ; Tripathi et al, 2016 ). In this regard, considering the availability of discarded lenticules deriving from the high number of SMILE procedures performed every year worldwide ( Lagali, 2020 ) it is important to mention the potential of banking lenticules after SMILE ( Trias et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Bioengineered Human Stromal Lenticule for Recombinant Human Nerve Growth Factor Release: A Potential Biocompatible Ocular Drug Delivery System

Mastropasqua

Nubile

Acerra

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Small incision lenticule extraction (SMILE), is a surgical procedure for the myopia correction, during which a corneal stromal lenticule is extracted. Given that we have previously demonstrated how this discarded tissue could be repurposed as a bio-scaffold for stromal engineering, this study aimed to explore its use as an ocular drug delivery system of active molecules, using neurotrophic factor Nerve Growth Factor (NGF). We employed human stromal lenticules directly collected from healthy donors undergoing SMILE. Following a sodium dodecylsulfate (SDS) treatment, decellularized lenticules were incubated with a suspension of polylactic-co-glycolic-acid (PLGA) microparticles (MPs) loaded with recombinant human NGF (rhNGF-MPs). Fluorescent MPs (Fluo-MPs) were used as control. Data demonstrated the feasibility to engineer decellularized lenticules with PLGA-MPs which remain incorporated both on the lenticules surface and in its stromal. Following their production, the in vitro release kinetic showed a sustained release for up to 1 month of rhNGF from MPs loaded to the lenticule. Interestingly, rhNGF was rapidly released in the first 24 h, but it was sustained up to the end of the experiment (1 month), with preservation of rhNGF activity (around 80%). Our results indicated that decellularized human stromal lenticules could represent a biocompatible, non-immunogenic natural scaffold potential useful for ocular drug delivery. Therefore, combining the advantages of tissue engineering and pharmaceutical approaches, this in vitro proof-of-concept study suggests the feasibility to use this scaffold to allow target release of rhNGF in vivo or other pharmaceutically active molecules that have potential to treat ocular diseases.

show abstract

“…In addition, Liu et al confirmed that long-term preservation with glycerol can reduce the activity of lenticule stromal cells, whether at room or low temperatures [23]. Considering the wide application prospects of SMILE-derived lenticules, Trias et al predicted that SMILE-derived lenticules will be brought into the eye bank for standardized preservation and management in the near future [24].…”

Section: Introductionmentioning

confidence: 99%

Carbodiimide crosslinked decellularized lenticules as a drug carrier for sustained antibacterial eye treatments

Rao¹,

Zhou²,

Chen³

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

In this study, the drug-loading and antibacterial activity of carbodiimide/N-hydroxysuccinimide (EDC/NHS) crosslinked decellularized lenticules (CDLs) were evaluated. Small incision lenticule extraction derived lenticules were decellularized and modified with crosslinking concentrations of 0.00 (E/L00, non-crosslinked), 0.01 (E/L01), 0.05 (E/L05) and 0.25 mmol (E/L25) EDC per mg lenticules at 5:1 EDC/NHS ratios with non-decellularized non-crosslinked lenticules (NDLs) as controls. NDLs and EDC/NHS CDLs had similar water contents. The light transmittance percentages (400–800 nm) were 91.55 ± 1.16%, 88.68 ± 1.19%, 80.86 ± 1.94%, 85.12 ± 2.42% and 85.62 ± 2.84% for NDLs, E/L00, E/L01, E/L05 and E/L25, respectively (P < 0.01). The EDC/NHS CDLs (diameter: 6.36 ± 0.18 mm; central thickness: 117.31 ± 3.46 μm) were soaked in 3% (wt./vol.) levofloxacin (LEV) solution for 3 h. The drug release concentrations of LEV-impregnated EDC/NHS CDLs were determined by high-performance liquid chromatography. Zone inhibition (ZOI) against Staphylococcus aureus of E/L01, E/L05 and E/L25 were superior to E/L00 CDLs (P < 0.01) and among the different crosslinked groups, E/L05 lenticules produced the largest ZOIs and their drug concentration release over 21 d was the highest. EDC/NHS crosslinking can improve the drug-loading effect and antibacterial activity of decellularized lenticules. LEV-impregnated EDC/NHS CDLs are promising drug delivery carriers.

show abstract

Banking of corneal stromal lenticules: a risk-analysis assessment with the EuroGTP II interactive tool

Cited by 7 publications

References 35 publications

Allogenic Lenticular Implantation for Correction of Refractive Error and Ectasia: Narrative Review

Allogenic Lenticular Implantation for Correction of Refractive Error and Ectasia: Narrative Review

Bioengineered Human Stromal Lenticule for Recombinant Human Nerve Growth Factor Release: A Potential Biocompatible Ocular Drug Delivery System

Carbodiimide crosslinked decellularized lenticules as a drug carrier for sustained antibacterial eye treatments

Contact Info

Product

Resources

About